AnaptysBio (NASDAQ:ANAB) Receives New Coverage from Analysts at SVB Leerink

SVB Leerink started coverage on shares of AnaptysBio (NASDAQ:ANAB) in a research report released on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $47.00 price target on the biotechnology company’s stock.

Several other research analysts also recently weighed in on ANAB. Wells Fargo & Company assumed coverage on AnaptysBio in a research note on Thursday, April 11th. They issued an overweight rating and a $56.00 target price on the stock. Piper Sandler initiated coverage on shares of AnaptysBio in a research report on Friday, February 16th. They set an overweight rating and a $80.00 price objective for the company. Wedbush raised shares of AnaptysBio from a neutral rating to an outperform rating and lifted their target price for the company from $20.00 to $34.00 in a report on Tuesday, March 12th. BTIG Research assumed coverage on shares of AnaptysBio in a report on Monday, February 26th. They set a buy rating and a $55.00 price target for the company. Finally, JPMorgan Chase & Co. reduced their price objective on shares of AnaptysBio from $30.00 to $28.00 and set a neutral rating for the company in a research report on Monday, April 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, AnaptysBio has a consensus rating of Moderate Buy and an average price target of $46.22.

AnaptysBio Stock Performance

Shares of ANAB stock opened at $21.34 on Tuesday. The firm has a market cap of $571.06 million, a price-to-earnings ratio of -3.51 and a beta of -0.30. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $27.50. The stock’s 50-day moving average is $23.42 and its two-hundred day moving average is $20.54.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) EPS for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The company had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. As a group, research analysts predict that AnaptysBio will post -6.25 EPS for the current year.

Insider Buying and Selling

In related news, insider Eric J. Loumeau sold 5,000 shares of AnaptysBio stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the transaction, the insider now directly owns 3,240 shares of the company’s stock, valued at $81,000. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other AnaptysBio news, CEO Daniel Faga sold 145,940 shares of the company’s stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $22.78, for a total value of $3,324,513.20. Following the sale, the chief executive officer now owns 752,087 shares of the company’s stock, valued at $17,132,541.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric J. Loumeau sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the insider now directly owns 3,240 shares of the company’s stock, valued at $81,000. The disclosure for this sale can be found here. Insiders have sold a total of 157,005 shares of company stock worth $3,586,199 in the last quarter. Company insiders own 35.50% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

A number of large investors have recently bought and sold shares of the stock. Hudson Bay Capital Management LP lifted its position in shares of AnaptysBio by 100.0% in the third quarter. Hudson Bay Capital Management LP now owns 100,000 shares of the biotechnology company’s stock valued at $1,796,000 after acquiring an additional 50,000 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in AnaptysBio by 4.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 206,785 shares of the biotechnology company’s stock valued at $3,714,000 after purchasing an additional 8,064 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in AnaptysBio by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 2,390 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of AnaptysBio during the 3rd quarter worth about $785,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of AnaptysBio by 134.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock worth $106,000 after buying an additional 3,381 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.